Updates on the Treatment and Management of Large Vessel Vasculitis
Résumé
Background: Large vessel vasculitis (LVV), encompassing giant cell arteritis (GCA) and Takayasu arteritis (TAK), causes granulomatous inflammation of large- and medium-sized arteries with potentially devastating ischemic complications. Glucocorticoids remain first-line therapy but carry significant long‑term morbidity.
Methods: This narrative review synthesizes current evidence on the classification, diagnosis, monitoring, and management of LVV, incorporating data from randomized controlled trials, meta‑analyses, and international guidelines.
Results: Advances in vascular imaging have improved diagnostic accuracy and increasingly supplement or replace temporal artery biopsy. In GCA, phase 3 trials have demonstrated that tocilizumab and upadacitinib have superior remission rates and glucocorticoid-sparing effects. In TAK, tumour necrosis factor inhibitors remain the preferred biologic for refractory disease, with emerging evidence supporting Janus kinase (JAK) inhibition and novel disease-modifying anti-rheumatic drug combinations.
Conclusion: Targeted therapies have transformed LVV management, though reliable biomarkers for disease activity and consensus on optimal treatment duration remain unmet needs.
Keywords: large vessel vasculitis, giant cell arteritis, Takayasu arteritis, tocilizumab, upadacitinib, glucocorticoid-sparing, JAK inhibitors
Références
Barra L, Pope JE, Pequeno P, Saxena FE, Bell M, Haaland D, et al. Incidence and prevalence of giant cell arteritis in Ontario, Canada. Rheumatology (Oxford). 2020;59(11):3250–3258. doi:10.1093/rheumatology/keaa095
Rutter M, Bowley J, Lanyon PC, Grainge MJ, Pearce FA. A systematic review and meta-analysis of the incidence rate of Takayasu arteritis. Rheumatology (Oxford). 2021;60(11):4982–4990. doi:10.1093/rheumatology/keab406
Reisch M, Thiel J, Bosch P. Large vessel vasculitis: recent advances in pathophysiology and targeted therapies. Drugs. 2026;86(6):909–925. doi:10.1007/s40265-026-02323-z
Watanabe R, Berry GJ, Liang DH, Goronzy JJ, Weyand CM. Pathogenesis of giant cell arteritis and Takayasu arteritis-similarities and differences. Curr Rheumatol Rep. 2020;22(10):68. doi:10.1007/s11926-020-00948-x
Cacoub P, Vieira M, Langford CA, Tazi Mezalek Z, Saadoun D. Large-vessel vasculitis. Lancet. 2025;406(10514):2017–2032. doi:10.1016/s0140-6736(25)01436-9
Maz M, Chung SA, Abril A, Langford CA, Gorelik M, Guyatt G, et al. 2021 American College of Rheumatology/Vasculitis Foundation Guideline for the management of giant cell arteritis and Takayasu arteritis. Arthritis Rheumatol. 2021;73(8):1349–1365. doi:10.1002/art.41774
Buttgereit F, Matteson EL, Dejaco C, Dasgupta B. Prevention of glucocorticoid morbidity in giant cell arteritis. Rheumatology (Oxford). 2018;57(suppl_2):ii11–ii21. doi:10.1093/rheumatology/kex459
Wilson JC, Sarsour K, Collinson N, Tuckwell K, Musselman D, Klearman M, et al. Serious adverse effects associated with glucocorticoid therapy in patients with giant cell arteritis (GCA): a nested case-control analysis. Semin Arthritis Rheum. 2017;46(6):819–827. doi:10.1016/j.semarthrit.2016.11.006
Ponte C, Grayson PC, Robson JC, Suppiah R, Gribbons KB, Judge A, et al. 2022 American College of Rheumatology/EULAR classification criteria for giant cell arteritis. Arthritis Rheumatol. 2022;74(12):1881-1889. doi:10.1002/art.42325
Grayson PC, Ponte C, Suppiah R, Robson JC, Gribbons KB, Judge A, et al. 2022 American College of Rheumatology/EULAR classification criteria for Takayasu arteritis. Arthritis Rheumatol. 2022;74(12):1872–1880. doi:10.1002/art.42324
Narváez J, Estrada P, Vidal-Montal P, Nolla JM. Performance of the new 2022 ACR/EULAR classification criteria for giant cell arteritis in clinical practice in relation to its clinical phenotypes. Autoimmun Rev. 2023;22(10):103413. doi:10.1016/j.autrev.2023.103413
Joseph G, Goel R, Thomson VS, Joseph E, Danda D. Takayasu arteritis: JACC Focus Seminar 3/4. J Am Coll Cardiol. Published online December 13, 2022. doi:10.1016/j.jacc.2022.09.051
alvarani C, Cantini F, Hunder GG. Polymyalgia rheumatica and giant-cell arteritis. Lancet. 2008;372(9634):234–245. doi:10.1016/s0140-6736(08)61077-6
Bosch P, Espigol-Frigolé G, Cid MC, Mollan SP, Schmidt WA. Cranial involvement in giant cell arteritis. Lancet Rheumatol. 2024;6(6):e384–e396. doi:10.1016/s2665-9913(24)00024-9
Espígol-Frigolé G, Dejaco C, Mackie SL, Salvarani C, Matteson EL, Cid MC. Polymyalgia rheumatica. Lancet. 2023;402(10411):1459–1472. doi:10.1016/s0140-6736(23)01310-7
van der Geest KSM, Sandovici M, Brouwer E, Mackie SL. Diagnostic accuracy of symptoms, physical signs, and laboratory tests for giant cell arteritis: a systematic review and meta-analysis. JAMA Intern Med. 2020;180(10):1295–1304. doi:10.1001/jamainternmed.2020.3050
Misra DP, Singh K, Rathore U, Kavadichanda CG, Ora M, Jain N, et al. Management of Takayasu arteritis. Best Pract Res Clin Rheumatol. 2023;37(1):101826. doi:10.1016/j.berh.2023.101826
Maleszewski JJ, Younge BR, Fritzlen JT, Hunder GG, Goronzy JJ, Warrington KJ, et al. Clinical and pathological evolution of giant cell arteritis: a prospective study of follow-up temporal artery biopsies in 40 treated patients. Mod Pathol. 2017;30(6):788–796. doi:10.1038/modpathol.2017.10
Majerovich K, Junek M, Khalidi N, Garner S. Duration of steroid therapy and temporal artery biopsy positivity in giant cell arteritis: a retrospective cohort study. J Rheumatol. 2023;50(7):965-966. doi:10.3899/jrheum.220860
Duhaut P, Pinède L, Bornet H, Demolombe-Ragué S, Dumontet C, Ninet J, et al. Biopsy proven and biopsy negative temporal arteritis: differences in clinical spectrum at the onset of the disease. Groupe de Recherche sur l’Artérite à Cellules Géantes. Ann Rheum Dis. 1999;58(6):335–341. doi:10.1136/ard.58.6.335
Dejaco C, Ramiro S, Bond M, Bosch P, Ponte C, Mackie SL, et al. EULAR recommendations for the use of imaging in large vessel vasculitis in clinical practice: 2023 update. Ann Rheum Dis. 2024;83(6):741–751. doi:10.1136/ard-2023-224543
Monti S, Bartoletti A, Bellis E, Delvino P, Montecucco C. Fast-track ultrasound clinic for the diagnosis of giant cell arteritis changes the prognosis of the disease but not the risk of future relapse. Front Med (Lausanne). 2020;7:589794. doi:10.3389/fmed.2020.589794
Sebastian A, van der Geest KSM, Tomelleri A, Macchioni P, Klinowski G, Salvarani C, et al. Development of a diagnostic prediction model for giant cell arteritis by sequential application of Southend Giant Cell Arteritis Probability Score and ultrasonography: a prospective multicentre study. Lancet Rheumatol. 2024;6(5):e291-e299. doi:10.1016/s2665-9913(24)00027-4
Broder MS, Sarsour K, Chang E, Collinson N, Tuckwell K, Napalkov P, et al. Corticosteroid-related adverse events in patients with giant cell arteritis: a claims-based analysis. Semin Arthritis Rheum. 2016;46(2):246–252. doi:10.1016/j.semarthrit.2016.05.009
Felten L, Leuchten N, Aringer M. Glucocorticoid dosing and relapses in giant cell arteritis-a single centre cohort study. Rheumatology (Oxford). 2022;61(5):1997–2005. doi:10.1093/rheumatology/keab677
Curumthaullee MF, Liozon E, Dumonteil S, Gondran G, Fauchais AL, Ly KH, et al. Features and risk factors for new (secondary) permanent visual involvement in giant cell arteritis. Clin Exp Rheumatol. 2022;40(4):734–740. doi:10.55563/clinexprheumatol/btj1ia
Langford CA, Cuthbertson D, Ytterberg SR, Khalidi N, Monach PA, Carette S, et al. A Randomized, double-blind trial of abatacept (CTLA-4Ig) for the treatment of giant cell arteritis. Arthritis Rheumatol. 2017;69(4):837–845. doi:10.1002/art.40044
Stone JH, Tuckwell K, Dimonaco S, Klearman M, Aringer M, Blockmans D, et al. Trial of tocilizumab in giant-cell arteritis. N Engl J Med. 2017;377(4):317–328. doi:10.1056/NEJMoa1613849
Blockmans D, Penn SK, Setty AR, Schmidt WA, Rubbert-Roth A, Hauge EM, et al. A phase 3 trial of upadacitinib for giant-cell arteritis. N Engl J Med. 2025;392(20):2013–2024. doi:10.1056/NEJMoa2413449
Misra DP, Singh K, Rathore U, Patro P, Tomelleri A, Campochiaro C, et al. The effectiveness of tocilizumab and its comparison with tumor necrosis factor alpha inhibitors for Takayasu arteritis: a systematic review and meta-analysis. Autoimmun Rev. 2023;22(3):103275. doi:10.1016/j.autrev.2023.103275
Sun X, Li J, Duan X, Wang Y, Chen Y, Zhang L, et al. Mycophenolate mofetil plus methotrexate versus cyclophosphamide with sequential azathioprine for treatment of Takayasu arteritis. Ann Rheum Dis. 2025;84(10):1733–1742. doi:10.1016/j.ard.2025.07.018
Mekinian A, Biard L, Dagna L, Novikov P, Salvarani C, Espitia O, et al. Efficacy and safety of TNF-α antagonists and tocilizumab in Takayasu arteritis: multicentre retrospective study of 209 patients. Rheumatology (Oxford). 2022;61(4):1376–1384. doi:10.1093/rheumatology/keab635
Nakaoka Y, Isobe M, Tanaka Y, Ishii T, Ooka S, Niiro H, et al. Long-term efficacy and safety of tocilizumab in refractory Takayasu arteritis: final results of the randomized controlled phase 3 TAKT study. Rheumatology (Oxford). 2020;59(9):2427–2434. doi:10.1093/rheumatology/kez630
Espitia O, de Boysson H, Heron E, Rodriguez-Regent C, Jousse S, Lapebie FX, et al. French recommendations for the use of imaging in giant cell arteritis. Joint Bone Spine. 2026;93(5):106073. doi:10.1016/j.jbspin.2026.106073
Clifford AH, Thai J, Yip A, Homik J, Vandermeer B, Kung JY, et al. How often does follow up 18F-FDG PET Improve in treated patients with giant cell arteritis: a systematic review and meta-analysis. J Rheumatol. 2026. Published online May 15, 2026. doi:10.3899/jrheum.2026-0050
Stone JH, Spotswood H, Unizony SH, Aringer M, Blockmans D, Brouwer E, et al. New-onset versus relapsing giant cell arteritis treated with tocilizumab: 3-year results from a randomized controlled trial and extension. Rheumatology (Oxford). 2022;61(7):2915–2922. doi:10.1093/rheumatology/keab780
Schmidt W, Setty AR, Dejaco C, Rubbert-Roth A, Cid MC, Ishii T, et al. OA17 Efficacy and safety of upadacitinib in giant cell arteritis: 2-year results from the re-randomized, double-blind SELECT-giant cell arteritis phase 3 trial. Rheumatology. 2026;65(Supplement_2). https://doi.org/10.1093/rheumatology/keag121.017
Buttgereit F, Dejaco C, Matteson EL, Dasgupta B. Polymyalgia rheumatica and giant cell arteritis: a systematic review. JAMA. 2016;315(22):2442–2458. doi:10.1001/jama.2016.5444
Kramarič J, Rotar Ž, Tomšič M, Hočevar A. Performance of leflunomide as a steroid-sparing agent in giant cell arteritis: a single-center, open-label study. Front Med (Lausanne). 2022;9:1069013. doi:10.3389/fmed.2022.1069013
Antonio AA, Santos RN, Abariga SA. Tocilizumab for giant cell arteritis. Cochrane Database Syst Rev. 2022;5(5):CD013484. doi:10.1002/14651858.CD013484.pub3
Zhu LM, Mendel A, Ross C, Makhzoum JP. The effectiveness and safety of leflunomide in the treatment of giant cell arteritis: a systematic review and meta-analysis. Rheumatol Adv Pract. 2025;9(4):rkaf128. doi:10.1093/rap/rkaf128
Téléchargements
Publié
Comment citer
Numéro
Rubrique
Licence
© Canadian Rheumatology Today 2026
Cette œuvre est sous licence Creative Commons Attribution - Pas d'Utilisation Commerciale - Pas de Modification 4.0 International.
